📰 Toronto Memory Program News
Page 3 - Toronto Memory Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Toronto Memory Program. Real-time updates on events, politics, business and more.
December 8, 2022
The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.
December 8, 2022
The experimental drug lecanemab was able to slow down Alzheimers in a large study. Many researchers think the drug will become the first to help large numbers of patients.
December 3, 2022
In a trial it slowed the disease’s progression and improved quality of life, yet there are risks.
December 2, 2022
The latest Alzheimer’s drug, lecanemab. has stoked enthusiasm among some, but octors tempered their excitement after new data was released Tuesday.
December 2, 2022
Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement,
November 30, 2022
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3...
November 30, 2022
STOCKHOLM, Nov. 30, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory
November 30, 2022
The drug lecanemab slowed the rate of cognitive decline among people with early Alzheimer's disease by 27 per cent, compared with placebo infusions, but some question if its potential safety concerns outweigh any benefits
November 30, 2022
Eisai has presented and published full data from the Phase 3 clinical trial for its Alzheimer’s disease drug lecanemab, with results showing a statistically significant slowing decline associated with the neurodegenerative disorder. While an accelerated approval decision is expected in early 2023, the latest trial data are key because they represent the confirmatory study that could support an application for full FDA approval.